Laferobion lyophilisate for solution for injections 1 ml. №10 vial

Description

Laferobion 1 ml Clinical characteristics.

Laferobion 1 ml Indications
The drug is used in the complex therapy of adults with:

acute and chronic viral hepatitis B (moderate and severe forms);
chronic hepatitis C;
acute and chronic septic diseases of a viral nature;
herpetic infections of various localization (shingles, multiple skin herpetic eruptions, genital herpes infection)
papillomatosis of the larynx;
malignant melanoma, uveal melanoma, renal cell carcinoma, superficially localized bladder cancer, ovarian and breast cancer, Kaposi’s sarcoma with HIV infection, chronic myeloid leukemia, hairy cell leukemia, non-Hodgkin’s lymphomas, basal cell skin mycosis (fungal cell carcinoma) …
Laferobion 1 ml Contraindications
Hypersensitivity to the components of the drug;
severe cardiovascular disease (uncontrolled congestive heart failure, recent myocardial infarction, severe arrhythmias);
psoriasis;
severe liver and / or kidney dysfunction, including metastases;
epilepsy and other diseases of the central nervous system (including functional);
chronic hepatitis against the background of progressive or decompensated liver cirrhosis;
chronic hepatitis in patients receiving or recently received immunosuppressive therapy (except for a short course of corticosteroids);
a history of autoimmune hepatitis or other autoimmune diseases;
the patient has thyroid dysfunction;
the presence of severe visceral disorders in patients with Kaposi’s sarcoma;
combination therapy with telbivudine;
oppression of the myeloid germ of hematopoiesis;
combination therapy with ribavirin in the case of using Laferobion® as part of combination therapy for chronic hepatitis C.

Application features
Mental and central nervous system (CNS) disorders

In some patients, during therapy with interferon alfa-2b and even after stopping treatment, mainly for the next 6 months, severe side effects from the central nervous system were observed, especially: depression, suicidal thoughts and suicidal attempts. In children and adolescents treated with interferon alfa-2b in combination with ribavirin, suicidal thoughts and suicide attempts were observed much more often than in adults (2.4% versus 1%) during treatment and within 6 months after the end of therapy … As with adults, children and adolescents have experienced other psychiatric side effects (eg, depression, emotional imbalance, and sleepiness). Other CNS effects, including aggressive behavior (sometimes directed against others, such as thoughts of murder), bipolar disorders, mania, confusion, and changes in mental status, have been observed with alpha interferon therapy. Patients should be closely monitored for any symptoms of psychiatric disorders. If such symptoms appear, the clinician should consider their potential severity and consider the need for adequate treatment. If the symptoms of mental disorders do not disappear, or if suicidal thoughts arise, it is recommended to discontinue treatment with Laferobion® and provide the patient with appropriate psychiatric care.